News
Published Data as of
In TRIUMPH-1, Eli Lilly reported that retatrutide reduced the apnea-hypopnea index (AHI) by up to an average of 36.1 events per hour at 80 weeks.1 In TRIUMPH-4, Lilly reported that retatrutide reduced WOMAC knee osteoarthritis pain by up to an average of 4.5 points (75.8%) at 68 weeks.1 PepBank's regulatory record lists retatrutide as not approved for any use.2
Eli Lilly and Company said it will present new data across its cardiometabolic health portfolio at ObesityWeek 2026. The meeting runs from November 14 to 17, 2026, in Washington, D.C.1 On November 15, 2026, Lilly shared TRIUMPH results for retatrutide in sleep apnea and knee osteoarthritis pain.1
The same Lilly release also gives Phase 2 results for EloraTZP. It reports new Zepbound results in adolescents with obesity too.1
TRIUMPH-1 studied retatrutide in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity or overweight. Lilly reported that AHI fell by up to an average of 36.1 events per hour (60.6%) at 80 weeks.1
TRIUMPH-2 studied adults with moderate-to-severe OSA, obesity or overweight and type 2 diabetes. There, retatrutide reduced AHI by up to an average of 28.4 events per hour (48.1%) at 80 weeks.1
TRIUMPH-4 studied retatrutide in adults with knee osteoarthritis pain and obesity or overweight. Lilly reported that WOMAC pain fell by up to an average of 4.5 points (75.8%) at 68 weeks.1
In a published randomized controlled trial in people with obesity and knee osteoarthritis, retatrutide lowered the WOMAC pain score more than placebo.4 In this trial in people, a studied subcutaneous dose of 9 mg changed the score by -3.5 points, versus -1.9 points with placebo.4 In the same trial in people, a studied subcutaneous dose of 12 mg changed it by -3.6 points, a difference of -1.8 versus placebo.4
| Trial | Participants | Reported change |
|---|---|---|
| TRIUMPH-1 | Adults with moderate-to-severe OSA and obesity or overweight | AHI down by up to an average of 36.1 events per hour (60.6%) at 80 weeks1 |
| TRIUMPH-2 | Adults with moderate-to-severe OSA, obesity or overweight and type 2 diabetes | AHI down by up to an average of 28.4 events per hour (48.1%) at 80 weeks1 |
| TRIUMPH-4 | Adults with knee osteoarthritis pain and obesity or overweight | WOMAC pain down by up to an average of 4.5 points (75.8%) at 68 weeks1 |
As of November 15, 2026, PepBank holds 54 studies that gave Retatrutide, with 380 results from them.3 It holds 39 publications with findings in people, 14 with findings in animals and 4 with laboratory findings in cells or tissue.3 The retatrutide studies in PepBank have 255 findings in people and 104 findings in animals.3
PepBank also lists 34 registered trials that test retatrutide.3 It holds 0 predicted findings from computer models for retatrutide.3
PepBank's regulatory record lists retatrutide as not approved for any use, in every place in the record.2 PepBank's regulatory record lists Tirzepatide as approved in the US and EU, as Mounjaro in 2022.5 The FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea and obesity in adults.1
PepBank lists 34 registered trials that test retatrutide and 254 that test tirzepatide.3,6 In PepBank's records, retatrutide vs tirzepatide shows 255 findings in people against 2050.3,6
Yes. The FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea and obesity in adults.1 The FDA indication also lists reducing and maintaining body weight in adults with obesity, with a reduced-calorie diet and more physical activity.7 PepBank holds 360 publications with findings in people for tirzepatide.6
Lilly reported a Phase 2 study of EloraTZP in adults with obesity or overweight and type 2 diabetes.1 Weight loss reached up to an average of 54.1 lbs (23.3%) at 48 weeks.1 Lilly said EloraTZP also lowered A1C by up to an average of 2.9%.1 In SURMOUNT-ADOLESCENTS, Zepbound reduced BMI by an average of 21.4% at 72 weeks in adolescents with obesity.1
Yes, in a randomized controlled trial in people with metabolic dysfunction-associated steatotic liver disease (MASLD).8 In this trial in people, mean liver fat fell by 42.9% from baseline with a studied subcutaneous dose of 1 mg once weekly.8 PepBank holds 39 publications with findings in people for retatrutide.3
Yes, in the published TRIUMPH-2 trial in people with obesity and type 2 diabetes. In this randomized controlled trial, a studied subcutaneous dose of 12 mg once weekly changed bodyweight by -18.8% at week 80. Bodyweight changed by -5.1% with placebo in the same trial in people.9
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated